[go: up one dir, main page]

MA40528A - Anticorps thérapeutiques qui se lient à oprf et oprl - Google Patents

Anticorps thérapeutiques qui se lient à oprf et oprl

Info

Publication number
MA40528A
MA40528A MA040528A MA40528A MA40528A MA 40528 A MA40528 A MA 40528A MA 040528 A MA040528 A MA 040528A MA 40528 A MA40528 A MA 40528A MA 40528 A MA40528 A MA 40528A
Authority
MA
Morocco
Prior art keywords
oprf
opri
antibody therapeutics
bind
oprl
Prior art date
Application number
MA040528A
Other languages
English (en)
Inventor
Gunnar F Kaufmann
Heyue Zhou
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MA40528A publication Critical patent/MA40528A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions et des méthodes se rapportant ou provenant d'anticorps anti-oprf et anti-oprl. Plus spécifiquement, cette invention concerne des anticorps entièrement humains qui se lient à oprf et oprl, à des fragments et des dérivés desdits anticorps se liant aux anticorps anti-oprf et anti-oprl, et des polypeptides se liant à oprf et oprl contenant lesdits fragments. L'invention concerne également des acides nucléiques codant pour ces anticorps, fragments et dérivés d'anticorps et
MA040528A 2014-08-29 2015-08-28 Anticorps thérapeutiques qui se lient à oprf et oprl MA40528A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462044107P 2014-08-29 2014-08-29

Publications (1)

Publication Number Publication Date
MA40528A true MA40528A (fr) 2017-07-05

Family

ID=55400714

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040528A MA40528A (fr) 2014-08-29 2015-08-28 Anticorps thérapeutiques qui se lient à oprf et oprl

Country Status (16)

Country Link
US (1) US9879069B2 (fr)
EP (1) EP3185897A4 (fr)
JP (1) JP2017526686A (fr)
KR (1) KR20170068456A (fr)
CN (1) CN107073096A (fr)
AU (1) AU2015308625A1 (fr)
BR (1) BR112017003983A2 (fr)
CA (1) CA2959165A1 (fr)
EA (1) EA201790489A1 (fr)
IL (1) IL250755A0 (fr)
MA (1) MA40528A (fr)
MX (1) MX2017002674A (fr)
PH (1) PH12017500368A1 (fr)
SG (1) SG11201701529YA (fr)
WO (1) WO2016033547A1 (fr)
ZA (1) ZA201701915B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426298A4 (fr) * 2016-03-10 2019-11-27 Viela Bio, Inc. Molécules de liaison à l'ilt7 et leurs méthodes d'utilisation
WO2017163049A1 (fr) * 2016-03-21 2017-09-28 Kymab Limited Anticorps anti-paludéens qui se lient à la protéine circumsporozoïte
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
JP7179719B2 (ja) * 2016-06-06 2022-11-29 ポリセリックス・リミテッド 抗体、その使用及びそのコンジュゲート
AU2019235900B2 (en) * 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same
JP7104458B2 (ja) * 2018-04-02 2022-07-21 上海博威生物医薬有限公司 リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69515613T2 (de) * 1994-12-16 2000-11-30 Chiron Behring Gmbh & Co. Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa
CA2742969A1 (fr) * 2008-11-07 2010-05-14 Fabrus Llc Anticorps anti-dll4 et utilisations associees
CA2822684A1 (fr) * 2010-12-23 2012-06-28 Intercell Austria Ag Agents oprf/i et leur utilisation chez des patients hospitalises et chez d'autres patients
RU2586687C2 (ru) * 2011-02-23 2016-06-10 Альцхем Аг Характеризующиеся высокой латентностью отвердители для эпоксидных смол
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1

Also Published As

Publication number Publication date
EP3185897A4 (fr) 2018-05-02
IL250755A0 (en) 2017-04-30
AU2015308625A1 (en) 2017-04-20
ZA201701915B (en) 2018-05-30
US20160060326A1 (en) 2016-03-03
BR112017003983A2 (pt) 2018-02-14
EA201790489A1 (ru) 2017-08-31
WO2016033547A8 (fr) 2017-04-06
US9879069B2 (en) 2018-01-30
SG11201701529YA (en) 2017-03-30
PH12017500368A1 (en) 2017-07-10
JP2017526686A (ja) 2017-09-14
WO2016033547A1 (fr) 2016-03-03
KR20170068456A (ko) 2017-06-19
CN107073096A (zh) 2017-08-18
MX2017002674A (es) 2017-09-19
EP3185897A1 (fr) 2017-07-05
CA2959165A1 (fr) 2016-03-03

Similar Documents

Publication Publication Date Title
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MA40528A (fr) Anticorps thérapeutiques qui se lient à oprf et oprl
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2022002364A (es) Anticuerpos anti-pd-l1.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EP4249515A3 (fr) Anticorps anti-cd3 humanisés ou chimériques
PH12018500684A1 (en) Agonistic antibodies specifically binding human cd40 and methods of use
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
NZ728688A (en) Anti-pd-1 antibodies
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
PH12018500906B1 (en) Antibodies specifically binding pd-1 and their uses
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12016501366A1 (en) Novel anti-baff antibodies
EP3872094A3 (fr) Anticorps ciblant un antigène de maturation des lymphocytes b et procédés d'utilisation
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
SG10201806454RA (en) Anti-tenascin c antibodies and uses thereof
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3